{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.7","upperLimit":"3.7","value":"3.7"},{"comment":"Due to the lack of available data caused by censoring subjects in the MEDI3617 + bevacizumab Q3W escalation cohorts for this endpoint, median duration of response was not calculable.","groupId":"OG001","lowerLimit":"17.8","upperLimit":"17.8","value":"NA"},{"comment":"Due to the lack of available data caused by censoring subjects in the MEDI3617 + bevacizumab Q2W cohorts for this endpoint, median duration of response was not calculable.","groupId":"OG002","lowerLimit":"2.9","upperLimit":"3.7","value":"NA"},{"comment":"Due to the lack of available data caused by censoring subjects in the MEDI3617 + paclitaxel cohorts for this endpoint, median duration of response was not calculable.","groupId":"OG003","lowerLimit":"1.6","upperLimit":"17.7","value":"NA"},{"comment":"No objective response was observed in the MEDI3617 + carboplatin/paclitaxel cohorts.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"description":"Duration of response is defined as the duration from the first documentation of objective disease response (ie, confirmed CR or confirmed PR) to the first documented disease progression. The duration of response was censored on the date of last tumor assessment documenting absence of disease progression for participants who have no documented progression prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Duration of response was evaluated for the subgroup of participants with an objective response using the Kaplan-Meier method.","dispersionType":"Full Range","groups":[{"description":"Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG000","title":"MEDI3617 SINGLE AGENT TOTAL"},{"description":"Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG001","title":"MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL"},{"description":"Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.","id":"OG002","title":"MEDI3617 + BEVACIZUMAB Q2W TOTAL"},{"description":"Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.","id":"OG003","title":"MEDI3617 + PACLITAXEL TOTAL"},{"description":"Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG004","title":"MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL"}],"paramType":"MEDIAN","populationDescription":"Safety population included all participants who received treatment with MEDI3617.","reportingStatus":"POSTED","timeFrame":"Time from the first dose of investigational product until end of study","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}